Lumos Pharma (LUMO) Peer Comparison

$4.34

$0.00 (0.00%)

As on 13-Dec-2024 09:30EDT

Market cap

$38 Mln

Revenue (TTM)

$2 Mln

P/E Ratio

--

P/B Ratio

7.6

Div. Yield

0 %

Edit

	Lumos Pharma (LUMO)	Longboard Pharmaceuticals (LBPH)	Pieris Pharmaceuticals (PIRS)
Market cap ($ Mln)	38	2,342	21
Revenue ($ Mln)	2	0	1
Net Profit ($ Mln)	-34.92	-76.34	-15.95
Net Margin (%)	-1,583.49	-954,300.00	-1,179.96
RoE (%)	-312.41	-25.93	-83.45
Price to Earnings	--	--	--
Price-To-Book	7.64	8.51	1.10

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Lumos Pharma (LUMO)	Longboard Pharmaceuticals (LBPH)	Pieris Pharmaceuticals (PIRS)
Operating Revenue	2.05	0.00	42.81
Cost of Revenue	0.04	0.01	41.80
Gross Profit	2.05	-0.01	1.01
Operating Expenses	38.67	56.76	72.57
Operating Profit (EBIT)	-36.61	-56.76	-29.76
Other Income	--	-0.53	--
Profit before Tax	-34.06	-54.42	-24.54
Provision for Tax	-0.03	-0.85	13.91
Profit after Tax (Net Income)	-34.03	-54.42	-24.54
Minority Interest	--	--	--
Consolidated Profit	-31.06	-43.95	--

Liabilities ($ Mln)

	Lumos Pharma (LUMO)	Longboard Pharmaceuticals (LBPH)	Pieris Pharmaceuticals (PIRS)
Shareholder's Funds	27.31	40.92	26.76
Minority Interest	--	--	--
Non-Current Liabilities	6.30	0.00	30.98
Current Liabilities	7.03	9.77	11.92
Total Liabilities	40.64	50.70	38.68

Assets ($ Mln)

	Lumos Pharma (LUMO)	Longboard Pharmaceuticals (LBPH)	Pieris Pharmaceuticals (PIRS)
Non-Current Assets	0.60	0.48	22.07
Current Assets	40.04	50.22	38.68
Total Assets	40.64	50.70	38.68
Total Debt*	0.59	0.48	13.10
Net Current Assets	33.01	40.45	36.84

Cashflow ($ Mln)

	Lumos Pharma (LUMO)	Longboard Pharmaceuticals (LBPH)	Pieris Pharmaceuticals (PIRS)
Cash From Operating Activities	-31.10	-50.87	-53.82
Cash Flow from Investing Activities	-11.36	-17.06	--
Cash from Financing Activities	-0.58	30.19	19.80
Net Cash Inflow / Outflow	--	-55.57	--

Ratios

Profitability Ratios

	Lumos Pharma (LUMO)	Longboard Pharmaceuticals (LBPH)	Pieris Pharmaceuticals (PIRS)
ROCE (%)	-77.61	-105.05	-72.41
ROE (%)	-78.34	-106.30	-89.76
ROA (%)	-60.27	-89.72	-36.58
EBIT Margin (%)	--	--	--
Net Margin (%)	-1,659.39	8,161.36	-57.33
Cash Profit Margin (%)	--	--	--

Growth Ratios

	Lumos Pharma (LUMO)	Longboard Pharmaceuticals (LBPH)	Pieris Pharmaceuticals (PIRS)
Revenue Growth (%)	0.35	--	0.65
EBIT Growth (%)	--	--	--
Net Profit Growth (%)	-9.57	-26.29	21.47
EPS Growth (%)	-0.12	0.09	--
Book Value Growth (%)	--	--	--

Valuation Ratios

	Lumos Pharma (LUMO)	Longboard Pharmaceuticals (LBPH)	Pieris Pharmaceuticals (PIRS)
Price / Earnings	-0.76	-2.65	--
Price / Book Value	0.94	3.53	--
Dividend Yield (%)	--	--	--
EV/EBITDA	0.27	-1.70	1.16
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	Lumos Pharma (LUMO)	Longboard Pharmaceuticals (LBPH)	Pieris Pharmaceuticals (PIRS)
Debt to Equity	0.02	0.01	0.47
Short term debt to equity ratio	0.02	0.01	0.03
Current Ratio	5.69	5.14	3.24
Quick Ratio	--	--	2.90
Interest Coverage	-36.66	-53.52	-3.26

Operating Efficiency Ratios

	Lumos Pharma (LUMO)	Longboard Pharmaceuticals (LBPH)	Pieris Pharmaceuticals (PIRS)
Debtors to sales (%)	10.24	--	1.34
Asset Turnover	0.04	0.00	0.64
Receivable days	38.56	--	27.23
Inventory Days	-954.12	--	35.71
Payable days	4,835.41	84,409.28	32.88
Cash Conversion Cycle	-4,217.92	--	30.06

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly